Previous 10 | Next 10 |
Athersys, Inc. (NASDAQ: ATHX) today announced financial results for the three and 12 months ended December 31, 2022, and provided a business update. Fourth Quarter 2022 and Recent Corporate and Operational Highlights Largely completed the company’s restructuring initiative wi...
2023-03-22 13:29:15 ET Gainers: GameStop ( GME ) +41% . Telesis Bio ( TBIO ) +31% . EZGO Technologies ( EZGO ) +33% . CorEnergy Infrastructure ( CORR ) +28% . 89bio ( ETNB ) +25% . JanOne ( JAN ) +27% . InMed Phar...
2023-03-22 10:02:09 ET Gainers: 89bio ( ETNB ) +38% . SCYNEXIS ( SCYX ) +21% . Athersys ( ATHX ) +20% . Sol-Gel Technologies ( SLGL ) +19% . LifeMD ( LFMD ) +11% . Losers: NuCana ( NCNA ) -10% . Nutex Hea...
2023-03-22 09:17:44 ET Athersys ( NASDAQ: ATHX ) said it was making planned amendments to a clinical trial of ischemic stroke therapy MultiStem following a Type B meeting with the U.S. Food & Drug Administration (FDA) on March 21. The company noted that it had ...
Primary Endpoint in Pivotal Acute Ischemic Stroke Trial Will Become mRS Shift Analysis at Day 365 Modifications Reflect Observations from Healios' Recently Completed TREASURE Trial in Japan and the Evolution of Stroke Standard of Care Athersys, Inc. (NASDAQ: ATHX) , ...
Novel Ultracold Storage System Ready for Commercial Licensing Athersys, Inc. (NASDAQ: ATHX) , a cell therapy and regenerative medicine company developing MultiStem ® ( invimestrocel ) for critical care indications, announced today that the United States Patent a...
Athersys ( NASDAQ: ATHX ) shares spiked ~8% pre-market Tuesday after announcing that the FDA granted a clinical Type B meeting to discuss the Phase 3 development of MultiStem, an experimental therapy targeted at ischemic stroke. The request for the meeting follows the data for Mul...
Athersys, Inc. (NASDAQ: ATHX) , a cell therapy and regenerative medicine company developing MultiStem ® ( invimestrocel ) for critical care indications, announced today that the Company has been granted a clinical Type B meeting with the U.S. Food & Drug Administration (FDA). T...
Athersys, Inc. (NASDAQ: ATHX) , a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announced today it will host a business update conference call on February 14, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Exec...
Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announced today its participation in two upcoming conferences, the International Stroke Conference 2023 (ISC) from February 8-10, 2023 in ...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...